Lyka Labs Ltd

LYKALABS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹426 cr, stock is ranked 1,277
High RiskStock is 3.84x as volatile as Nifty
148.807.05 (+4.97%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹426 cr, stock is ranked 1,277
High RiskStock is 3.84x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
-36.96
PB RatioPB Ratio
-17.50
Dividend YieldDiv. Yield
Sector PESector PE
38.74
Sector PBSector PB
5.18
Sector Div YldSctr Div Yld
0.66%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lyka Labs Limited is a pharmaceutical products and services provider. The Company is primarily engaged in formulation and manufacturing lyophilized products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202165.3972.8766.3387.81-17.27-5.56-60.54-11.55
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.38%

See detailed holdings

Recent EventsAll events 

Updates 
Announced OnNov 24, 2021

Lyka Labs Limited has informed the Exchange regarding 'Public Announcement to Equity Shareholders of Lyka Labs Limited'. | Download

Lyka Labs Limited has informed the Exchange regarding 'Public Announcement to Equity Shareholders of Lyka Labs Limited'. | Download

Public Announcement-Open Offer 
Announced OnNov 24, 2021

Arihant Capital Markets Ltd ("Managers to the Offer") has submitted to the Exchange a copy of Public Announcement for Open offer of Lyka Labs Limited ("Target Company") | Download

Arihant Capital Markets Ltd ("Managers to the Offer") has submitted to the Exchange a copy of Public Announcement for Open offer of Lyka Labs Limited ("Target Company") | Download

Reply to Clarification Sought 
Announced OnNov 2, 2021

LYKALABS: The Exchange had sought clarification from Lyka Labs Limited with respect to announcement dated 29-Oct-2021, regarding merger of Lyka Exports Limited with Lyka Labs Limited. On basis of above the Company was required to clarify following: 1. Brief details of change in shareholding pattern (if any) of listed entity; 2. Name of the entity (ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.; 3. Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length; 4. Area of business of the entity (ies); 5. Rationale for amalgamation/ merger; 6. In case of cash consideration amount or otherwise share entitlement/exchange ratio. The response of the Company is attached. | Download

LYKALABS: The Exchange had sought clarification from Lyka Labs Limited with respect to announcement dated 29-Oct-2021, regarding merger of Lyka Exports Limited with Lyka Labs Limited. On basis of above the Company was required to clarify following: 1. Brief details of change in shareholding pattern (if any) of listed entity; 2. Name of the entity (ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.; 3. Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length; 4. Area of business of the entity (ies); 5. Rationale for amalgamation/ merger; 6. In case of cash consideration amount or otherwise share entitlement/exchange ratio. The response of the Company is attached. | Download

See all events